Clarity Pharmaceuticals: Receives $3.26m R&D refund

Clarity Pharmaceuticals Receives $3.26m R&D refund

  • Clarity Pharmaceuticals (CU6) has received a research and development (R&D) tax refund of more than $3.26 million for FY21
  • The refund is part of The Australian Federal Government’s R&D tax incentive, recognising the R&D undertaken by Clarity in the radiopharmaceutical field
  • The R&D tax incentive is a program by the Australian Federal Government the encourages companies to engage and invest in R&D activities
  • Clarity will use the $3.26 million to further finance the development of its Targeted Copper Theranostics (TCT) platform of products for various cancer indications
  • Shares in Clarity are trading up 2.84 per cent to 72.5 cents
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

Experian Launches Credit Score App in ChatGPT, Enhancing Financial Access

New tool enables users to check credit scores effortlessly via ChatGPT.Highlights: Experian's app allows users to check credit...

US Senate Passes Bill Banning Issuance of CBDCs

Legislation aims to restrict the development of digital currencies by the Federal Reserve.Highlights: The US Senate approved a...

Truist Expands Open Banking Offerings with Plaid Partnership

Collaboration aims to enhance customer access to financial services.Highlights: Truist collaborates with Plaid for open banking expansion.The partnership...

UK’s National Fraud Database Reports 444,000 Fraud Cases in 2025

Cifas reveals a significant rise in reported fraud incidents across the UK.Highlights: Cifas reported 444,000 fraud cases in...